Stephanie Lynch

Stephanie Lynch

Auto-generated profile, based on publicly available information

Stephanie Lynch

Faculty of Medicine and Health, The University of Sydney, NSW, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Infection & Chemotherapy
Verified
Journal Article
Open access
SLShinwon Lee
Shinwon Lee
SLStephanie Lynch
Stephanie Lynch
Ruby CY LinRuby CY Lin
Ruby CY Lin
HMHeejoon Myung
Heejoon Myung
JIJonathan R Iredell
Jonathan R Iredell
Lee S, et al. Infect Chemother. 2023 Dec;55:e54. https://doi.org/10.3947/ic.2023.0067

22 July 2025 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
MPMartin Plymoth
Martin Plymoth
SLStephanie A. Lynch
Stephanie A. Lynch
AKAmeneh Khatami
Ameneh Khatami
HSHolly A. Sinclair
Holly A. Sinclair
DPDavid L. Paterson
David L. Paterson
JIJonathan R. Iredell
Jonathan R. Iredell
Due to the rise in antimicrobial resistance, there has been an increased interest in phage therapy to treat multidrug-resistant infections. In Australia, phage therapy is predominantly used in small clinical studies or for compassionate use; however, despite its potential expansion in modern medicine, the perception of phage therapy among medical professionals remains largely unknown. We conducted a national survey of Australian infectious diseases and clinical microbiology advanced trainees and specialists using an online mailing list to assess their knowledge, areas of interest, and concerns around the use of phage therapy in clinical practice in Australia; with 92 eligible respondents. Most respondents believed that the current national plan for controlling antimicrobial resistance is inadequate and that phage therapy may be an effective solution; with 87 (97%) indicating that they would consider using phage therapy meeting established guidelines for purity and safety. There was a preference for bespoke therapy, with Gram-negative pathogens highlighted as priority targets. Alongside the phage therapy delivery protocols, therapeutic phage monitoring was considered important. Cystic fibrosis, lung-infections, prosthetic device/related infections, and infections among patients following transplantation and/or immunosuppression were highly ranked in terms of priorities for clinical syndromes. Accessibility was highlighted as a barrier to phage therapy, specifically, timely access (n = 66; 72%) and logistics of phage procurement and administration (n = 64; 70%). These results suggest the support of phage therapy among infectious diseases and clinical microbiology advanced trainees and specialists in Australia, and highlights areas of focus and priority in order to advance phage therapy.

6 July 2023 in medRxiv
Verified
Preprint
Open access
PDF file
MPMartin Plymoth
Martin Plymoth
SLStephanie A. Lynch
Stephanie A. Lynch
AKAmeneh Khatami
Ameneh Khatami
HSHolly A. Sinclair
Holly A. Sinclair
JSJessica C. Sacher
Jessica C. Sacher
JIJonathan R. Iredell
Jonathan R. Iredell
Due to the rise in antimicrobial resistance (AMR), there has been an increased interest in phage therapy to treat multi-drug resistant infections. In Australia, phage therapy is predominantly used in small clinical studies or for compassionate use, however, despite its potential expansion in modern medicine, the perception of phage therapy among medical professionals remains largely unknown. Therefore, we conducted a national survey of Australian infectious diseases and clinical microbiology advanced trainees and specialists to assess their knowledge, areas of interest, and concerns around the use of phage therapy in clinical practice in Australia. Our survey received 92 responses from infectious diseases and clinical microbiology professionals across all states of Australia. The majority of those surveyed believed that the current national plan for controlling AMR is inadequate and that phage therapy may be an effective solution; with 97% of respondents indicating that they would consider using phage therapy meeting established guidelines for purity and safety (United States Food and Drug Administration and/or European Union guidelines). The respondents indicated a preference for bespoke therapy, with Gram-negative pathogens highlighted as priority targets. Alongside the phage therapy delivery protocols, therapeutic phage monitoring (TPM; like therapeutic drug monitoring (TDM)) was considered important. Cystic Fibrosis, lung-infections, prosthetic device related infections, and infections among patients following transplantation and/or immunosuppression were highly ranked in terms of priorities for clinical syndromes. Accessibility was highlighted as a barrier to phage therapy, specifically timely access (72%) and logistics of phage procurement and administration (70%). Altogether, these results suggest the support of phage therapy among infectious diseases and clinical microbiology advanced trainees and specialists in Australia, and highlights areas of focus and priority in order to advance phage therapy in modern medicine.

31 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
KWK. Watts
K. Watts
Ruby CY LinRuby CY Lin
Ruby CY Lin
SLS. A. Lynch
S. A. Lynch
JWJ. Warning
J. Warning
JBJ. J. Barr
J. J. Barr
JIJ. R. Iredell
J. R. Iredell
Objective: As antimicrobial resistance (AMR) continues to threaten global public health, bacteriophage therapy products (BTPs) offer a promising alternative to conventional antimicrobials. However, translation into routine clinical practice requires best practice standards for manufacturing and quality control to ensure the consistent safety, quality, and reliability of personalised BTPs produced for individual patients or small cohorts. Design: A modified Delphi methodology was used to develop consensus statements, engaging experts from Australia’s National Bacteriophage Therapy Regulatory Working Group across the fields of clinical microbiology, phage biology, good manufacturing practice (GMP), regulatory science, and government. The process comprised three iterative phases: (1) structured statement development, (2) an anonymous REDCap survey, and (3) a hybrid consensus meeting. The strength of evidence and recommendations was assessed using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework. Results: Consensus was reached on 35 statements to provide best practice manufacture and quality control guidance for BTPs. These statements address requirements for phage identification and characterisation; define the point at which GMP-aligned processes commence for ubiquitous phages; outline quality control expectations for phage active pharmaceutical ingredient (pAPI) production and maintenance of BTP and host cell repositories. Additional guidance covers quality management systems, including documentation, traceability, and governance. Conclusion: These consensus statements provide comprehensive best practice recommendations for the manufacture and quality control of BTPs in Australia. By promoting consistent, safe, and quality-assured approaches to personalised BTPs, they aim to facilitate clinical implementation while remaining aligned with existing international pharmacopoeial standards and regulatory frameworks. Significance of this study: What is already known on this subject?: Bacteriophage Therapy Products (BTPs) have re-emerged as a potential solution to antimicrobial resistance (AMR), supported by growing clinical evidence and global research activity. Data available to the regulatory working party includes more than 70 high-risk patients treated with dozens of different bacteriophages under a national open-label protocol (unpubl.). Published guidance from the European Pharmacopoeia, European Medicines Agency (EMA), UK Medicines & Healthcare products Regulatory Agency (MHRA), and World Health Oragnization (WHO) exists, yet no practical standards for personalised BTP manufacture have been established. What are the new findings?: Recommendations have been made to define minimum quality and manufacturing stasndards for the safe, consistent production of BTPs. This is the first expert endorsed, risk-based framework to support the translation of personliased BTPs into routine clinical practice, cobering manufacture, repository management, quality control and supply. How might it impact on clinical practice in the foreseeable future?: These consensus statements, developed by Australia’s National Bacteriophage Therapy Regulatory Working Group, can assist researchers, clinicians and regulatory authorities to develop BTP production protocols.

16 May 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SLStephanie Lynch
Stephanie Lynch
HSHolly Sinclair
Holly Sinclair
AKAmeneh Khatami
Ameneh Khatami
NMNicki Mileham
Nicki Mileham
JSJessica C Sacher
Jessica C Sacher
JIJonathan Iredell
Jonathan Iredell
Cystic fibrosis (CF) is the most prevalent serious inherited disease in Australia, imposing significant health risks. CF is characterised by chronic lung inflammation and recurrent pulmonary infections that increase morbidity and premature mortality rates. The emergence of antimicrobial resistance (AMR) places further challenges on the treatment and management of CF, necessitating research into alternative strategies for treatment of bacterial infections. Bacteriophage therapy, involving bacterial-specific viruses, is a potential avenue for AMR infections in patients with CF. Existing literature supports the feasibility of phage therapy in CF but there has been a gap in investigating attitudes of the CF community including affected individuals and their caregivers, regarding phage therapy. Understanding perspectives and needs of the CF community is essential for successful implementation and acceptance of novel therapies including phage therapy. We conducted a survey that encompasses responses from 112 consumers from across Australia, comprising people living with CF (38.4%), parents of affected children (49.6%), carers (6.4%), and family members (3%). The findings showed a significant reliance on antibiotics with 51.4% requiring oral, 43.4% nebulised, and 11.4% intravenous (IV) antibiotics within the preceding 2 weeks. Respondents highlighted the availability of new treatments, duration of hospitalisations and costs associated with treatment as important priorities to address. Despite an awareness of phage therapy among 62.4% of respondents, 86.4% expressed interest in obtaining more information, primarily from medical staff (66.7%). Notably, 96.0% of respondents expressed willingness to participate in phage therapy trials. The results of this survey highlighted the CF community’s strong interest in advanced therapeutic approaches, specifically phage therapy. The findings reveal a notable recognition and acceptance of phage therapy as a viable treatment option for pulmonary infections associated with CF.

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
SLShinwon Lee
Shinwon Lee
SLStephanie Lynch
Stephanie Lynch
NZNouri Ben Zakour
Nouri Ben Zakour
GCGeoffrey Coombs
Geoffrey Coombs
HMHeejoon Myung
Heejoon Myung
JIJonathan Iredell
Jonathan Iredell
Timely access is a major concern when considering phage therapy. Using susceptible phage is critical for the outcomes of phage therapy. For timely access to susceptible phages, identifying factors associated with phage susceptibility and building a reference set (RS) to compare host ranges is needed. Phage K, which was a well-documented lytic S. aureus phage, and phage PBSA02, which was a new S. aureus phage from the Korean phage biobank, were used. The efficiency of plating (EOP), the relative activity of phage against specific strain/host strain, and growth kinetics assays were used to determine phage susceptibility. The isolates with high lytic activity (HLA) were defined as susceptible (EOP > 1%). The phage PBSA02 and phage K susceptible groups were compared to the non-susceptible groups to determine the associating factors of phage susceptibility. We constructed a methicillin-resistant S. aureus (MRSA) RS using the Australian Group on Antimicrobial Resistance (AGAR) repository. We determined the predominant sequence types (ST) of MRSA in Australia in 2021; ST22 accounted for 90.1% of HA-MRSA and 5 STs for 67.9% of CA-MRSA (figure 1). Then, we randomly selected 39 AGAR MRSA isolates corresponding to each ST from each region in Australia (figure 1). Phage PBSA02 exhibited HLA against 56.4% of the 39 RS isolates, while phage K exhibited HLA against 30.8%. Phage PBSA02 showed HLA against 100% of ST93 and ST30 isolates following ST1 (62.5%), ST22 (37.5%), ST5 (20%) and ST45 (16.7%); phage K showed HLA against 100% of ST30 and 62.5% of ST22 isolates but against none of the ST93 isolates. Our study demonstrated that phage susceptibility was associated with the STs of MRSA, and the RS could be useful for a standardised comparison of the phage host range. Phage PBSA02 with broad susceptibility to the RS could be useful for phage therapy. Further work includes antibiotic synergy testing and resistance mechanism identification in these isolates. All Authors: No reported disclosures